Sleep Disordered Breathing and Its Impact on Neuro-cognitive Performance and Quality of Life in Parkinson Disease
Status: | Completed |
---|---|
Conditions: | Insomnia Sleep Studies, Parkinsons Disease, Pulmonary |
Therapuetic Areas: | Neurology, Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 4/21/2016 |
Start Date: | June 2011 |
End Date: | March 2016 |
The purpose of this study is to determine the impact of sleep and breathing problems during
sleep on memory, attention, and general well being (quality of life) in people with
Parkinson Disease.
sleep on memory, attention, and general well being (quality of life) in people with
Parkinson Disease.
During the 2 year award period, we will prospectively enroll 200 patients with idiopathic
Parkinson Disease (PD), who meet eligibility criteria below. All patients will undergo a
baseline polysomnography (PSG) to diagnose Sleep Disordered Breathing (SDB) and will be
asked to complete validated questionnaires to measure Sleep Quality, SDB risk, insomnia
severity, daytime sleepiness, presence of restless leg syndrome (RLS), anxiety/depression,
and quality of life. Medical records will be reviewed to determine co-morbidities and
medication use. Each PD participant will undergo a full neurological examination, including
the Unified Parkinson's Disease Rating Scale (UPDRS), the Hoehn & Yahr stage and a battery
of neuro-cognitive measures at baseline. Patients with SDB will be offered PAP titration and
treatment for 4 months. All patients (SDB [PAP compliant, non-compliant], and no SDB
[controls]) will complete repeat neuro-cognitive evaluation, questionnaires, neurological
evaluation and UPDRS assessment at 4 month and at 1 year follow-up. PD participants will be
assessed in the "on" state in the morning. In the event that a participant goes "off" during
testing, a break will be taken and participants will be given the option of taking their
medication to return to the "on" state and resume testing or they can return later in the
week to complete the evaluation. Although participants will understand the general purpose
of the study, they will be blinded to the major study hypothesis. Neuropsychological
examiners and the neurologist conducting the neurological exam will be blinded to the SDB
status of the patient. Four month follow-up will be staggered according to enrolment date
and will be completed by Year 2.
Parkinson Disease (PD), who meet eligibility criteria below. All patients will undergo a
baseline polysomnography (PSG) to diagnose Sleep Disordered Breathing (SDB) and will be
asked to complete validated questionnaires to measure Sleep Quality, SDB risk, insomnia
severity, daytime sleepiness, presence of restless leg syndrome (RLS), anxiety/depression,
and quality of life. Medical records will be reviewed to determine co-morbidities and
medication use. Each PD participant will undergo a full neurological examination, including
the Unified Parkinson's Disease Rating Scale (UPDRS), the Hoehn & Yahr stage and a battery
of neuro-cognitive measures at baseline. Patients with SDB will be offered PAP titration and
treatment for 4 months. All patients (SDB [PAP compliant, non-compliant], and no SDB
[controls]) will complete repeat neuro-cognitive evaluation, questionnaires, neurological
evaluation and UPDRS assessment at 4 month and at 1 year follow-up. PD participants will be
assessed in the "on" state in the morning. In the event that a participant goes "off" during
testing, a break will be taken and participants will be given the option of taking their
medication to return to the "on" state and resume testing or they can return later in the
week to complete the evaluation. Although participants will understand the general purpose
of the study, they will be blinded to the major study hypothesis. Neuropsychological
examiners and the neurologist conducting the neurological exam will be blinded to the SDB
status of the patient. Four month follow-up will be staggered according to enrolment date
and will be completed by Year 2.
Inclusion Criteria:
- Able to give consent.
- ≥18 years and have a Hoehn and Yahr stage at the time of enrollment of ≤3, clinical
diagnosis of idiopathic Parkinson's Disease meeting the United Kingdom Parkinson's
Disease Society Brain Bank criteria.
- Stable medical condition, including medications in the 1 month prior to enrollment.
Exclusion Criteria:
- Previous diagnosis of SDB with active use of Positive Airway Pressure (PAP), surgery
for SDB or tracheostomy.
- Inability to read and comprehend English and/or Spanish at a grade 5 level.
- Prior history of neurosurgical procedures for PD or any other condition.
- Diagnosis of dementia as defined by Mini-mental state examination (MMSE) of < 26.
- History of major uncontrolled psychiatric illness.
- History of drug or alcohol abuse/dependence.
- History of major head injury or other neurological disease.
- Patients with observable craniofacial abnormalities that may be a relative
contraindication to PAP.
We found this trial at
1
site
University of Miami A private research university with more than 15,000 students from around the...
Click here to add this to my saved trials